



Attorney Docket # 4948-2PCIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Carlos PICORNELL DARDER et al.

Serial No.: 09/491,624

Filed: January 26, 2000

For: Oral Pharmaceutical Preparation Comprising an  
Antiulcer Activity Compound, and Process for  
its Production

Group Art: 1615

I hereby certify that this correspondence is being  
deposited with the United States Postal Service with  
sufficient postage as first class mail in an envelope  
addressed to: Assistant Commissioner for Patents,  
Washington, D.C. 20231, on

August 27, 2001

(Date of Deposit)

Vincent M. Fazzari

Name of applicant, assignee or Registered Representative

Signature

August 27, 2001

Date of Signature

**REQUEST FOR CORRECTION OF FILING RECEIPT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

SIR:

Attached is a copy of the official filing receipt received from the U.S. Patent and  
Trademark Office in the above-identified application.

There is an error in:

☐ Applicants' name and/or address

☐ Title

☐ Filing Date

☐ Serial Number

☒ Priority Data (number)

☐ Incorrect Priority Date

☐ Other [pls specify]

which should read as follows: PCT PCT/ES98/00204 7/13/98 Spain P 9900157 1/27/99

It is respectfully requested that a corrected filing receipt be issued.

Respectfully submitted,  
COHEN, PONTANI, LIEBERMAN & PAVANE

By: 

Vincent M. Fazzari  
Reg. No. 26,879  
551 Fifth Avenue, Suite 1210  
New York, New York 10176  
(212) 687-2770

Dated: August 27, 2001

## FILING RECEIPT



\*OC000000005001469\*

UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark OfficeAddress: ASSISTANT SECRETARY AND  
COMMISSIONER OF PATENT AND TRADEMARKS  
Washington, D.C. 20231

RECEIVED  
 SEP 10 2000  
 TECO CENTER 1600/2900

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/491,624	01/26/2000	1615	462	4948-2PCIP	8	33	2

Thomas C. Pontani Esquire  
 Cohen Pontani Lieberman & Pavane  
 551 Fifth Avenue Suite 1210  
 New York, NY 10176

Date Mailed: 03/21/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Carlos Picornell Darder, Madrid, SPAIN;

## Continuing Data as Claimed by Applicant

## Foreign Applications

SPAIN P 9701816 07/31/1997  
 PCT PCT/ES98/00204 01/27/1999

COHEN, PONTANI, LIEBERMAN &amp; PAVANE

MAR 24 2000

If Required, Foreign Filing License Granted 03/21/2000

RECEIVED

\*\* SMALL ENTITY \*\*

## Title

Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production

## Preliminary Class

424

Data entry by : HINES, BRENDA

Team : OIPE

Date: 03/21/2000





**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**RECEIVED**  
SEP 10 2001  
TECH CENTER 1600/2600

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**PLEASE NOTE the following information about the Filing Receipt:**

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, DC 20231

**FILE COPY**

## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov



Bib Data Sheet

CONFIRMATION NO. 8816

<b>SERIAL NUMBER</b> 09/491,624	<b>FILING DATE</b> 01/26/2000 <b>RULE</b>	<b>CLASS</b> 424	<b>GROUP ART UNIT</b> 1615	<b>ATTORNEY DOCKET NO.</b> 4948-2PCIP	
<b>APPLICANTS</b> Carlos Picornell Darder, Madrid, SPAIN;					
<b>** CONTINUING DATA *****</b>					
<b>** FOREIGN APPLICATIONS *****</b> PCT/ES98/00204 07/13/1998 SPAIN P 9900157 01/27/1999					
<b>IF REQUIRED, FOREIGN FILING LICENSE GRANTED** SMALL ENTITY **</b> ** 03/21/2000					
Foreign Priority claimed <input type="checkbox"/> yes <input type="checkbox"/> no		<b>STATE OR COUNTRY</b> SPAIN	<b>SHEETS DRAWING</b> 8	<b>TOTAL CLAIMS</b> 33	<b>INDEPENDENT CLAIMS</b> 2
35 USC 119 (a-d) conditions met <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance					
Verified and Acknowledged		Examiner's Signature		Initials	
<b>ADDRESS</b> THOMAS C. PONTANI, ESQ. COHEN PONTANI LIEBERMAN & PAVANE 551 FIFTH AVENUE SUITE 1210 NEW YORK, NY 10176					
<b>TITLE</b> Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production					
<b>FILING FEE RECEIVED</b> 462	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees		
			<input type="checkbox"/> 1.16 Fees ( Filing )		
			<input type="checkbox"/> 1.17 Fees ( Processing Ext. of time )		
			<input type="checkbox"/> 1.18 Fees ( Issue )		
			<input type="checkbox"/> Other _____		
			<input type="checkbox"/> Credit		